Scandion Oncology receives approval for initiating the CORIST part 2 trial
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that the company has obtained approval from the Danish Medicines Agency and the Ethics Com-mittee in Denmark of the amendment of part 2 of the CORIST Phase II study. This means that the company can commence the inclusion of patients. To increase the recruitment rate, Scandion Oncology is expanding the number of sites in Denmark from 2 to 5 and will further add additional sites in the EU.“With this approval, we can now commence part 2 of this seminal study. This next step in our journey will target a clear proof-of-